Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
Frequently Asked Questions / Types of Cancer / Gastrointestinal Cancers / Gastric Cancer
John Han-Chih Chang, MD and Kenneth Blank, MD
Last Modified: November 1, 2001
Dear Editors,
My husband and I are stationed in England. We just recently received information from back home that my mother has been diagnosed with stomach cancer. We are in the dark being so far away from home. Could you help us find information about this disease and what complications may arise? If you could lead us in the right direction, that would be greatly appreciated. Thank you ever so much.
Sincerely,
TW
John Han-Chih Chang, MD and Kenneth Blank, MD, Editorial Assistants for OncoLink, respond:
Dear TW,
hank you for your interest and question.
Stomach or gastric cancer is the second most common cause of cancer death in the world, but it is not frequent entity in the United States. It has a higher incidence in Japan and other Asian countries. It is associated with diets high in nitrosamines or meat preservatives found in smoked or salted foods. It has also been linked to chronic atrophic gastritis.
The problem with gastric cancers is that they are usually diagnosed in more advanced stages, because early lesions are asymptomatic. Most have spread beyond the stomach to the regional lymph nodes or directly into the adjacent organs or structures. This would indicate a poor prognosis.
The mainstay of treatment at this time is radical surgery with removal of the primary gastric tumor with the entire stomach or part of it. This is reconnected with an anastamosis to the small bowels. Some advocate diagnostic and/or therapeutic extensive dissection of all regional lymph nodes. This technique has been supported strongly by the Japanese. Most believe, however, that this procedure does not improve outcome.
There have been studies that have revealed a 40% ? 80% local failure rate. This means that the tumor reappears in the operative bed and/or regional lymph nodes after surgery alone 40-80% of the time. Due to the possible lack of success with surgery alone, new avenues were pursued with adjuvant chemotherapy and/or radiation therapy post-operatively or definitively (for those who are not surgical candidates).
Randomized trials of treatment post surgery have revealed that chemotherapy alone patients fair worse than those that receive radiation combined with chemotherapy in improving loco-regional recurrence. However, minimal evidence has been demonstrated whether any of this helpful in survival improvement compared to surgery alone. In other words, it is preferable to spare the patient the possible side effects of radiation and/or chemotherapy until such time as that they need those treatments. This remains a very controversial issue with the significant studies having been performed by the gastrointestinal tumor study group and the Europeans.
There is a current national trial underway randomizing patients to adjuvant treatment post-operatively versus no further therapy. This trial's results may finally answer the question of the utility of adjuvant therapy in gastric cancer. There has been literature in support of using adjuvant therapy for poor prognostic indices such as positive lymph nodes and margins. Again, the jury is still out. Despite all the negative literature about adjuvant therapy, we believe in certain incidences that the loco-regional cancer control is essential to a significant quality of life.
As always, please discuss these issues with your mother's cancer physicians.
As an oncologist, Dr. Giantonio provides care for many patients at the end of life, which he describes as a privilege and rewarding. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

